# US 2026/0241068 A1 · Mixed-surface polyamidoamine polymer variants and methods of use thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0241068 A1
- Document ID: US20260241068A1
- Status: Published application
- Kind: A1
- Application number: 19/127,034
- Filed: 2023-11-06
- Published: 2026-08-20
- Earliest claimed: 2022-11-04
- Applicants: Duke University
- Inventors: Bruce SULLENGER; Lyra OLSON; Rachel REMPEL; Nicole HUNTER
- Web page: https://patentgrep.com/patent/US20260241068A1

## CPC

- A61L 15/26: Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof {(A61L15/225 takes precedence)}
- A61L 27/18: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- A61L 27/34: Macromolecular materials
- A61L 2400/12: Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

The present disclosure provides mixed-surface polyamidoamine (PAMAM) polymers comprising cationic surface groups and neutral surface groups. Also provided are scavenging apparatuses, microfibers, filters, and other devices comprising the mixed-surface polymers. The disclosure further provides methods of using the mixed-surface polymers for treatment, detection, and prevention of diseases and conditions characterized by high levels of inflammatory mediators.

## Claims

### Claim 1

A mixed-surface polyamidoamine (PAMAM) polymer comprising a plurality of surface groups, wherein the surface groups comprise cationic surface groups and neutral surface groups, wherein between about 30% and about 70% of the surface groups are neutral.

### Claim 2 (depends on 1)

The PAMAM polymer of claim 1, wherein the surface groups consist of cationic surface groups and neutral surface groups, wherein between about 30% and about 70% of the surface groups are neutral.

### Claim 3 (depends on 1)

The PAMAM polymer of claim 1, wherein the polymer is a G3 polymer or a G4 polymer.

### Claim 4 (depends on 1)

The PAMAM polymer of claim 1, wherein about 50% of the surface groups are neutral.

### Claim 5 (depends on 1)

The PAMAM polymer of claim 1, wherein the neutral surface groups comprise hydroxyl groups.

### Claim at position 6

-11. (canceled)

### Claim 12 (depends on 1)

A method of treating cancer in a subject comprising administering a therapeutically effective amount of the PAMAM polymer of claim 1 to the subject.

### Claim 13 (depends on 1)

A method of treating cancer in a subject comprising contacting a bodily fluid from a subject with the PAMAM polymer of claim 1, wherein the contacting removes invasion-promoting or metastatic molecules or particles from the bodily fluid of the subject.

### Claim 14 (depends on 12)

The method of claim 12, wherein the cancer is selected from the group consisting of pancreatic, ovarian, colon, liver, brain, breast, and lung cancer.

### Claim 15 (depends on 1)

A method for reducing inflammatory mediators in a bodily fluid of a subject, the method comprising: contacting the bodily fluid with the PAMAM polymer of claim 1 wherein the contacting step reduces the concentration of the inflammatory mediators in the bodily fluid.

### Claim 16 (depends on 15)

The method of claim 15, wherein the subject suffers from a condition associated with an abnormally high concentration of inflammatory mediators.

### Claim 17 (depends on 16)

The method of claim 16, wherein the condition is an autoimmune disease, an infectious disease, or an inflammatory effect of radiation therapy or exposure to radiation.

### Claim 18 (depends on 13)

The method of claim 13, wherein the contacting step is performed within the subject.

### Claim 19 (depends on 13)

The method of claim 13, wherein the contacting step is performed outside the subject.

### Claim 20 (depends on 19)

The method of claim 19, further comprising obtaining the bodily fluid from the subject before the contacting step.

### Claim 21 (depends on 20)

The method of claim 20, further comprising returning the bodily fluid to the subject.

### Claim 22 (depends on 13)

The method of claim 13, wherein the contacting step is performed during dialysis or in conjunction with extracorporeal membrane oxygenation.

### Claim 23 (depends on 13)

The method of claim 13, wherein the bodily fluid is blood, lymph, plasma, serum, urine or cerebral spinal fluid.

### Claim 24 (depends on 12)

The method of claim 12, wherein the PAMAM polymer is administered to the subject via a route selected from the group consisting of oral, topical, intranasal, intraperitoneal, parenteral, intravenous, intramuscular, subcutaneous, intrathecal, transcutaneous, nasopharyngeal, intratumoral, and transmucosal.

### Claim 25 (depends on 12)

The method of claim 12, further comprising administering a therapeutic agent or radiation to the subject.

### Claim at position 21

-51. (canceled)

### Claim 52

A PAMAM composition comprising a plurality of nanofibers, the nanofibers comprising a plurality of mixed-surface polyamidoamine (PAMAM) polymers,
wherein the nanofibers are less than 2 μm in diameter, and
wherein each of the PAMAM polymers comprises cationic surface groups and neutral surface groups, wherein between about 30% and about 70% of the surface groups are neutral.

### Claim at position 23

-64. (canceled)
